Shanghai Pushi Medical Files for A-Share IPO, SIPG Group Holds 5.99% Stake as Fourth-Largest Shareholder

This article originates from: Financial World

Financial World, January 21st, by reporter — Recently, the Capital Market Electronic Information Disclosure Platform released the coaching filing report of Shanghai Push Medical Devices Co., Ltd. (hereinafter referred to as "Shanghai PushMed").

On January 17, 2022, Shanghai Push Medical Devices Co., Ltd. (PushMed) signed a coaching agreement with China International Capital Corporation Limited. The law firm involved is Grandall Law Firm (Shanghai), and the accounting firm is BDO China Shu Lun Pan Certified Public Accountants LLP.

Shanghai Push Medical Devices Co., Ltd. was established in 2012 as a supplier of interventional medical devices for cardiovascular and cerebrovascular diseases, integrating research, manufacturing, and sales. Based on micro-piercing integrated processing technology, the company’s LACbes left atrial appendage occluder received "Special Approval for Innovative Medical Devices" from the China Food and Drug Administration (CFDA) in 2017 and was approved for marketing in 2019. The company has also developed a series of interventional medical devices for congenital heart diseases, including Patent Ductus Arteriosus Occluder (PDAO), Atrial Septal Defect Occluder (ASDO), Ventricular Septal Defect Occluder (VSDO), Occluder Delivery System (Delivery System), and Snare, which have been widely used in major hospitals across China.

Tianyancha information shows that Shanghai Push Medical Devices Co., Ltd. conducted an equity financing in September 2020, with Shanghai International Port (Group) Co., Ltd. as the investor. Currently, Shanghai International Port (Group) Co., Ltd. is the fourth largest shareholder of the company, holding a 5.99% stake.